Iberia Pharmaceuticals, a prominent player in science-backed skincare and wellness solutions, has unveiled plans for a new 60,000 sq. ft. manufacturing and research hub in Jhajjar, Haryana. Backed by an investment of approximately ₹70 crores, the facility is expected to be operational by mid-2026 and will operate under the Government of India’s Make in India initiative.

The upcoming plant is engineered to meet stringent global manufacturing and quality control standards, with a focus on sustainable operations. Equipped with advanced process control systems and cutting-edge technology, the unit will cater to large-scale commercial manufacturing without compromising on compliance or product performance.

At full capacity, the facility will be capable of producing over 12 million units annually in dermatology, wellness, and chronic care for both domestic and international markets. It is also expected to create more than 600 new jobs, further contributing to the regional economy.

In addition to high-volume manufacturing, the site will feature advanced research laboratories dedicated to continuous product innovation. These R&D capabilities will support Iberia’s portfolio in nanotechnology-driven skincare and therapeutic solutions with a strong pharmaceutical foundation, including vegan, high-performance formulations.

Nitin Jain, Founder of Iberia Pharmaceuticals, said, “By bringing world-class manufacturing capabilities to India, we are strengthening trust, building capacity, and setting higher benchmarks for healthcare quality. This facility is a major step forward in our growth strategy and reaffirms our commitment to delivering globally compliant, high-quality products for Indian and international consumers.”

Saurav Ojha, Co-Founder, added, “Our goal is to push the boundaries of skincare innovation while remaining grounded in safety, precision, and responsibility. This facility is not just an expansion—it’s a statement of our commitment to science-led, accessible healthcare solutions.”

Also read: ENTOD Pharmaceuticals Unveils Breakthrough R&D Innovations in Ophthalmology and Dermatology

Iberia Pharmaceuticals currently offers a range of clinically tested, internationally recognised brands such as Sesderma, Mediderma, Dermpix, Noreva, and Metacare, serving both consumers and healthcare professionals. With decades of experience in dermatology and a growing footprint in wellness, the company continues to position itself as a trusted partner in the healthcare value chain.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!